Neuraxpharm Group

Neuraxpharm Group, established in 1985, is a prominent European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders. Operating within the Healthcare and Pharmaceuticals sectors, the company has built a significant presence across Europe. Its core mission revolves around providing a comprehensive portfolio of proven, differentiated, and affordable CNS treatment options. This strategic focus allows Neuraxpharm Group to serve a broad spectrum of patients, healthcare professionals, and industry partners with specialized therapeutic solutions.

With a workforce of 500 - 1,000 employees distributed across 21 locations, Neuraxpharm Group demonstrates substantial operational capacity. The company's product range encompasses various pharmaceutical ingredients and specialty pharmaceuticals designed for CNS conditions. This extensive offering is supported by a dedicated team, and insights into their leadership and structure can be found by visiting Meet Neuraxpharm Group's team. Their commitment to advancing CNS care is evident in their continuous development and distribution of essential medications.

Generating an annual revenue of $546.4M, Neuraxpharm Group plays a vital role in the European pharmaceutical market. The company's business model emphasizes accessibility and efficacy, ensuring that patients receive necessary treatments. By concentrating on specialty pharmaceuticals for CNS disorders, Neuraxpharm Group addresses critical unmet medical needs. Their operations span multiple European countries, solidifying their position as a key player in the region's healthcare ecosystem and a reliable partner for medical advancement.